Navigation Links
ULURU Inc. to Present at the 8th World Biomaterials Congress
Date:5/28/2008

- Invited Oral Presentation by Dr. John St. John - - Three Poster Presentations on the Hydrogel Nanoparticle Technology -

ADDISON, Texas, May 28 /PRNewswire-FirstCall/ -- ULURU Inc. (Amex: ULU) today announced that at the upcoming 8th World Biomaterials Congress, to be held in Amsterdam from May 28th to June 1, 2008, Dr. John St. John, ULURU's Vice President of Material Science, will give an invited oral presentation along with the presentation of three posters.

The title of the invited oral presentation is "Strategies for Tissue Regeneration in Wound Healing with Controlled Release of Actives from Hydrogel Nanoparticle Wound Dressings". This presentation will be made in the session "Tissue Repair and Regeneration" to be conducted on June 1, 2008.

A poster titled "Control of Vascular Proliferation and Healing in Acute Wounds with Controlled Release of VEGF from Hydrogel Nanoparticle Dressings" will be presented in a session on May 31, 2008. Additionally, two posters will be presented at the "Biomaterials for Plastic Surgery -- Poster Session" on May 31, 2008. The titles of these posters are "Formulation and Preclinical Evaluation of Hydrogel Nanoparticle-Hyaluronic Acid Dermal Fillers" and "Hydrogel Nanoparticle Gels as Breast Implant Filler Materials."

Commenting on the upcoming presentation Dr. John St. John stated "I am very pleased to be an invited speaker at this prestigious Biomaterials Congress. This Congress gives ULURU the opportunity to showcase our hydrogel nanoparticle aggregate technology along with a portion of the extensive body of work that we have accumulated supporting our product developments. Additionally, this is an ideal forum to present a representative part of the extensive data that we have generated on the controlled release of active agents to improve wound healing."

Utilizing the experience we are gaining in the United States, we are planning to roll out the launch of Altrazeal(TM), ULURU's first wound dressing utilizing our nanoparticle aggregate technology, extensively throughout the world in the upcoming 12 months. Activities are ongoing to secure a CE mark designation by year-end 2008 which would enable Altrazeal(TM) to be marketed throughout Europe and other international markets. The initial wound dressing containing an active agent, silver, an anti microbial and anti bacterial agent, has recently completed the necessary GLP toxicology studies and we expect to file for 510k approval with the FDA in the second half of 2008.

About ULURU Inc.:

ULURU Inc. is a specialty pharmaceutical company focused on the development of a portfolio of wound management, oral care and plastic surgery products to provide patients and consumers improved clinical outcomes through controlled delivery utilizing its Hydrogel Nanoparticle Aggregate technology and innovative transmucosal delivery system. For further information about ULURU Inc., please visit our website at http://www.uluruinc.com.

This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, including but not limited to statements made relating to our expectation of filing a 510k in the second half of 2008, the expectation of rolling out the launch of Altrazeal(TM) extensively throughout the world in the upcoming 12 months and the expectation of securing of a CE Mark designation by year-end 2008. These statements are subject to numerous risks and uncertainties, including but not limited to the risk factors detailed in the Company's Annual Report on Form 10-KSB for the year ended December 31, 2007, Quarterly Report on Form 10-Q for the quarter ended March 31, 2008 and other reports filed by us with the Securities and Exchange Commission.

Contact: Company

Kerry P. Gray

President & CEO

Terry K. Wallberg

Vice President & CFO

(214) 905-5145


'/>"/>
SOURCE ULURU Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. CV Therapeutics Announces Presentations at the American Diabetes Association 68th Scientific Sessions
2. CryoLife to Present at FBR Capital Markets Annual Spring Investor Conference
3. Inverness Medical Innovations to Present at FBR Capital Markets 12th Annual Spring Investor Conference on May 28, 2008
4. Amylin Pharmaceuticals to Present at Annual Meeting of Stockholders
5. Amylin Pharmaceuticals to Present at FBR Capital Markets Investor Conference
6. SuperGen to Present at FBR Capital Markets 12th Annual Spring Investor Conference on May 29, 2008
7. AVANT Immunotherapeutics Announces Oral Presentation of CDX-110 at ASCO Annual Meeting
8. West Pharmaceutical Services to Present at the 2008 UBS Global Specialty & Generic Pharmaceuticals Conference
9. Martek to Present at Upcoming UBS Conference
10. eResearchTechnology to Present at the FBR 12th Annual Spring Investor Conference on May 28th 2008
11. Presentation of Landmark Clinical Trial Evaluating Endoscopic Treatment for Pre-cancerous Condition of Esophagus
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2016)... ... April 27, 2016 , ... PathSensors, ... Scientific Advisory Board. Dr. Lamka will assist PathSensors in expanding the use of ... PathSensors deploys the CANARY® test platform for the detection of harmful pathogens, including ...
(Date:4/27/2016)... ... ... Global Stem Cells Group and the University of Santiago Biotechnology ... development initiatives for potential stem cell protocol management for 2016 – 2020. , ... meeting to establish a working agenda and foster initiatives to promote stem cell research ...
(Date:4/26/2016)... LOS ANGELES, Calif. (PRWEB) , ... April 27, ... ... Los Angeles office of Lewis Roca Rothgerber Christie LLP as an associate in ... and prosecuting U.S. and international electrical, mechanical and electromechanical patent applications. He has ...
(Date:4/26/2016)... ... April 26, 2016 , ... ... announces the latest technology innovation for its Volume Pattern Generator (VPG) line of ... production of advanced photomasks as well as a solution for mid volume direct ...
Breaking Biology Technology:
(Date:3/11/2016)... Germany , March 11, 2016 http://www.apimages.com ... - Cross reference: Picture is available at AP Images ( http://www.apimages.com ... from DERMALOG will be used to produce the new refugee identity ... other biometric innovations, at CeBIT in Hanover ... scanner from DERMALOG will be used to produce the new refugee ...
(Date:3/10/2016)... , March 10, 2016 ... new market research report "Identity and Access Management Market ... Audit, Compliance, and Governance), by Organization Size, by Deployment, ... 2020", published by MarketsandMarkets, The market is estimated to ... 12.78 Billion by 2020, at a Compound Annual Growth ...
(Date:3/9/2016)... 2016 This BCC Research report provides an ... RNA Sequencing (RNA Seq) market for the years 2015, ... and reagents, data analysis, and services. Use ... RNA-Sequencing market such as RNA-Sequencing tools and reagents, RNA-Sequencing ... affecting each segment and forecast their market growth, future ...
Breaking Biology News(10 mins):